What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet

In the FUTURE-C-Plus phase II trial, patients with advanced previously untreated immune-enriched triple-negative breast cancer achieved an overall objective response rate of 81.3% with the combination of camrelizumab, famitinib, and nab-paclitaxel. This supports that the quantity of immune cells is important for identifying those with response to treatments combined with PD-1-targeting immunotherapy. See related article by Chen et al., p. 2807.